Oral News and Research

RSS

Decision Resources: Atrial fibrillation drug market to increase more than sevenfold

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, owing to the launches of several new agents, the atrial fibrillation drug market will increase more than sevenfold from $790 million in 2008 to $6.1 billion in 2018 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.

15 Dec 2009

Updated clinical data from Phase 2 study evaluating oral ridaforolimus presented

ARIAD Pharmaceuticals, Inc. today announced the presentation of updated clinical data from its Phase 2 study evaluating oral ridaforolimus in combination with trastuzumab (Herceptin®) in patients with resistant, metastatic breast cancer.

15 Dec 2009

Alexza Pharmaceuticals submits its NDA for Staccato loxapine to FDA

Alexza Pharmaceuticals, Inc. today announced that it has submitted its New Drug Application (NDA) for Staccato® loxapine (AZ-004) to the US Food and Drug Administration (FDA).

15 Dec 2009

ZYPREXA RELPREVV approved by FDA

The U.S. Food and Drug Administration (FDA) approved ZYPREXA RELPREVV (olanzapine) For Extended Release Injectable Suspension for the treatment of schizophrenia in adults, Eli Lilly and Company announced today.

14 Dec 2009

Researchers develop new method for individually adapted implants

Researchers at Mid Sweden University, together with Professor Jan Hirsch and Consultant Per Dérand, oral & maxillofacial surgeons at Uppsala University Hospital and Mälarsjukhuset Hospital, respectively, have developed an entirely new method for individually adapted implants.

14 Dec 2009

CTRC-AACR San Antonio Breast Cancer Symposium presents new data on emerging breast cancer therapies

Breast cancer continues to be a dynamic field of research, and the CTRC-AACR San Antonio Breast Cancer Symposium, now in its 32nd year, is the premier destination to present new data on emerging therapies.

14 Dec 2009

AVAC: MDP 301 effectiveness trial finds no evidence that PRO 2000 microbicide reduces HIV infection

The Microbicides Development Programme announced earlier today that its MDP 301 effectiveness trial, which was conducted among almost 9,400 women in four African countries, found no evidence that the PRO 2000 microbicide reduces the risk of HIV infection.

14 Dec 2009

Scientists evaluate current research on soy infant formula

Members of the media are invited to attend a press availability period at noon on Friday, December 18, 2009 that will follow a scientific meeting evaluating the safety of soy infant formula. An independent panel of 14 scientists will evaluate the most current research on soy infant formula to determine whether exposure to soy infant formula is a risk to human development.

14 Dec 2009

Diabetic patients exposed to insulin glargine have higher incidence of cancer, shows study

Type 2 diabetes and obesity are linked to an increased risk of certain cancers. Recently published studies suggested that insulin glargine (a synthetic insulin preparation marketed under the trade name Lantus), may be associated with a higher risk of certain cancers than other insulins or oral glucose lowering medications.

14 Dec 2009

Pfizer announces results from studies evaluating neratinib

Pfizer Inc. today announced results from studies evaluating neratinib (HKI-272), an investigational, orally administered, pan-ErbB inhibitor, in patients with human epidermal growth factor receptor-2 (HER2, also known as ErbB2) positive breast cancer at the 2009 CTRC-AACR San Antonio Breast Cancer Symposium (SABCS).

14 Dec 2009

Results from Phase 2 trial evaluating Nexavar with capecitabine and paclitaxel presented

Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc. today announced results from two collaborative group-sponsored randomized, double-blind, placebo-controlled Phase 2 trials were presented at the 32nd Annual San Antonio Breast Cancer Symposium (SABCS).

14 Dec 2009

Ipsen announces preliminary results of phase I trial in metastatic breast cancer with BN83495

Ipsen today announced the preliminary results of a phase I trial in metastatic breast cancer with BN83495, Ipsen’s lead and first-in-class orally available irreversible steroid sulfatase (STS) inhibitor.

14 Dec 2009

Incyte announces positive results from ongoing Phase I/II clinical trial for INCB7839

Incyte Corporation announced today positive results from an ongoing Phase I/II clinical trial for its selective oral sheddase inhibitor, INCB7839, involving 46 patients with HER2 positive metastatic breast cancer.

14 Dec 2009

Positive interim results of ARRY-380 in Phase 1 trial announced

Array BioPharma Inc. today announced positive interim results of its novel, small molecule HER2 (ErbB2) inhibitor, ARRY-380, in a Phase 1 trial in advanced cancer patients.

13 Dec 2009

University of Maryland School of Nursing to spearhead new Center for Pain Studies

The University of Maryland School of Nursing in Baltimore is "uniquely poised" to spearhead a new collaborative Center for Pain Studies funded by a $2.4 million, five-year federal grant, said Susan Dorsey, PhD, RN, director of the center.

11 Dec 2009

New data suggests bisphosphonate drug may play a role in reducing recurrent breast cancer

Bisphosphonates are routinely given to women with postmenopausal breast cancer, but new data suggests that these agents may play a role in reducing recurrent breast cancer as well.

11 Dec 2009

Nutritional supplements to strengthen immunity and improve periodontal health

The PA periodontists in Dr. David DiGiallorenzo's Collegeville and Williamsport practice recently began offering two lines of nutritional supplements to patients as a means of promoting the connection between good nutrition and improved periodontal health.

11 Dec 2009

Senior research scientist to receive 2009 Astellas USA Foundation Award

Fredrick Khachik, Ph.D., a senior research scientist in the Department of Chemistry and Biochemistry at the University of Maryland, College Park, has been chosen to receive a 2009 Astellas USA Foundation Award.

11 Dec 2009

Tasigna demonstrates greater efficacy over Gleevec in chronic Ph+ CML patients

In a large Phase III clinical trial, Tasigna (nilotinib capsules) demonstrated greater efficacy over Gleevec (imatinib) in the treatment of adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase. The new clinical data were just presented as a late breaking abstract at the 51st annual meeting of the American Society of Hematology (ASH), in New Orleans, Louisiana.

11 Dec 2009

DMC recommends Novartis and Nordic Bioscience to continue oral calcitonin Phase III studies

Unigene Laboratories, Inc. (http://www.unigene.com) announced that an independent Data Monitoring Committee (DMC) has recommended that Novartis and its partner Nordic Bioscience proceed as planned with their ongoing oral calcitonin Phase III studies for osteoporosis and osteoarthritis.

11 Dec 2009

Oral News and Research

Decision Resources: Atrial fibrillation drug market to increase more than sevenfold

Updated clinical data from Phase 2 study evaluating oral ridaforolimus presented

Alexza Pharmaceuticals submits its NDA for Staccato loxapine to FDA

ZYPREXA RELPREVV approved by FDA

Researchers develop new method for individually adapted implants

CTRC-AACR San Antonio Breast Cancer Symposium presents new data on emerging breast cancer therapies

AVAC: MDP 301 effectiveness trial finds no evidence that PRO 2000 microbicide reduces HIV infection

Scientists evaluate current research on soy infant formula

Diabetic patients exposed to insulin glargine have higher incidence of cancer, shows study

Pfizer announces results from studies evaluating neratinib

Results from Phase 2 trial evaluating Nexavar with capecitabine and paclitaxel presented

Ipsen announces preliminary results of phase I trial in metastatic breast cancer with BN83495

Incyte announces positive results from ongoing Phase I/II clinical trial for INCB7839

Positive interim results of ARRY-380 in Phase 1 trial announced

University of Maryland School of Nursing to spearhead new Center for Pain Studies

New data suggests bisphosphonate drug may play a role in reducing recurrent breast cancer

Nutritional supplements to strengthen immunity and improve periodontal health

Senior research scientist to receive 2009 Astellas USA Foundation Award

Tasigna demonstrates greater efficacy over Gleevec in chronic Ph+ CML patients

DMC recommends Novartis and Nordic Bioscience to continue oral calcitonin Phase III studies

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News